SciBase Establishes New Financial Path with Share Issues
The board of directors of SciBase Holding AB (publ) has officially declared a new share issue aimed to raise about SEK 19 million to Castle Biosciences, Inc. This strategic move is part of a broader effort to enhance the company's growth and market presence. Additionally, plans are in place for another directed share issue of roughly SEK 11 million to strengthen the ownership base.
Details of the Share Issues
The first directed issue (Directed Issue I) allows SciBase to raise approximately SEK 19 million. This amount is derived from the sale of no more than 47,886,950 new shares. Castle Biosciences is committed to acquiring all shares in this issue, which is contingent upon regulatory approval. The anticipated outcome of this first directed issue is set to be disclosed no later than a few months from now, allowing stakeholders insight into the company's trajectory.
Furthermore, subject to approval at the upcoming general meeting, SciBase plans to roll out an additional share issue (Directed Issue II) to Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS, and Ribbskottet AB. This second issue is designed to attract SEK 11 million and will follow similar terms to the initial issue.
Strategic Implications of the Investments
Chairman of the Board, Jesper Høiland, has expressed pride in the collaboration with Castle Biosciences, emphasizing the positive impact on SciBase's market positioning. He believes that these financial maneuvers will facilitate faster market entry for innovative solutions targeted at enhancing dermatological diagnostics.
Engaging with Life Science Industry Leaders
Pia Renaudin, the CEO of SciBase, noted the significance of having strong backing from respected investors like Life Science Invest. This partnership is seen as a validation of SciBase's ongoing strategies and its potential in the U.S. market, which is anticipated to grow rapidly due to increasing interest from clinics.
Innovating in Dermatological Technology
SciBase is at the forefront of medical technology, committed to advancing early detection and prevention of skin diseases. The company's flagship product, Nevisense, employs advanced algorithms and electrical impedance spectroscopy technology to achieve superior diagnostic accuracy.
With the introduction of Nevisense in the U.S., the company is making ambitious efforts to establish this technology as a standard within dermatology. The early figures reveal impressive sales growth, doubling in the U.S. market and receiving strong support from leading physicians in the field.
Future Directions for SciBase
Beyond its current initiatives, SciBase is also focusing on developing future products, especially in addressing skin conditions like atopic dermatitis. With ongoing collaborations aimed at creating diagnostic tests using Nevisense's EIS technology, the company is poised for continued innovation in treating dermatological diseases.
Financial Outlook and Shareholder Impact
The directed share issues will significantly increase the total number of shares from 338,295,633 to 414,182,583, thus increasing the share capital accordingly. While this may lead to a dilution of approximately 18.3% for current shareholders, the board believes the strategic benefits outweigh the downsides.
The decisive factors for opting for directed share issues over rights issues were thoroughly analyzed. The board concluded that the time and resources required for a rights issue would be counterproductive against the company’s immediate strategic goals.
Frequently Asked Questions
1. What is the purpose of the new share issues announced by SciBase?
The new share issues are aimed at raising capital to enhance market penetration, particularly in the U.S., and to fund product development initiatives.
2. Who are the primary investors in these directed share issues?
The primary investors include Castle Biosciences, Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS, and Ribbskottet AB.
3. How much capital is SciBase expecting to raise from these issues?
SciBase aims to raise approximately SEK 19 million from the first issue and SEK 11 million from the second issue.
4. What technology is SciBase developing for dermatology?
SciBase is focusing on its Nevisense platform that combines artificial intelligence with electrical impedance spectroscopy for accurate skin disease diagnostics.
5. How does the increased share count impact existing shareholders?
The increase in share count may lead to dilution of existing shareholders' stakes by approximately 18.3%, but the board believes this strategy supports long-term growth.
